Literature DB >> 21383500

CXCL1 and its receptor, CXCR2, mediate murine sickle cell vaso-occlusion during hemolytic transfusion reactions.

Jung-Eun Jang1, Eldad A Hod, Steven L Spitalnik, Paul S Frenette.   

Abstract

Hemolytic transfusion reactions (HTRs) can produce serious and potentially life-threatening complications in sickle cell disease (SCD) patients; however, the mechanisms underlying these complications remain undetermined. We established a model of alloimmune, IgG-mediated HTRs in a well-characterized humanized murine model of SCD. HTRs induced acute vaso-occlusive crisis (VOC), resulting in shortened survival of SCD mice. Acute VOC was associated with elevated circulating inflammatory chemokine levels, including striking elevation of the levels of the neutrophil chemoattractant CXCL1. Recombinant CXCL1 administration was sufficient to induce acute VOC in SCD mice, characterized by leukocyte recruitment in venules, capture of circulating red blood cells, reduction of venular flow, and shortened survival. In contrast, blockade of the CXCL1 receptor, CXCR2, prevented HTR-elicited acute VOC and prolonged survival in SCD mice. These results indicate that CXCL1 is a key inflammatory mediator of acute VOC in SCD mice. Targeted inhibition of CXCL1 and/or CXCR2 may therefore represent a new therapeutic approach for acute VOC in SCD patients.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21383500      PMCID: PMC3069787          DOI: 10.1172/JCI45336

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  23 in total

1.  Critical role for CXCR2 and CXCR2 ligands during the pathogenesis of ventilator-induced lung injury.

Authors:  John A Belperio; Michael P Keane; Marie D Burdick; Vedang Londhe; Ying Ying Xue; Kewang Li; Roderick J Phillips; Robert M Strieter
Journal:  J Clin Invest       Date:  2002-12       Impact factor: 14.808

2.  Hypoxia/reoxygenation causes inflammatory response in transgenic sickle mice but not in normal mice.

Authors:  D K Kaul; R P Hebbel
Journal:  J Clin Invest       Date:  2000-08       Impact factor: 14.808

3.  Primary role for adherent leukocytes in sickle cell vascular occlusion: a new paradigm.

Authors:  Aslihan Turhan; Linnea A Weiss; Narla Mohandas; Barry S Coller; Paul S Frenette
Journal:  Proc Natl Acad Sci U S A       Date:  2002-03-05       Impact factor: 11.205

4.  Risk of alloimmunization and delayed hemolytic transfusion reactions in patients with sickle cell disease.

Authors:  J V Cox; E Steane; G Cunningham; E P Frenkel
Journal:  Arch Intern Med       Date:  1988-11

5.  Interleukin 8 as a vaso-occlusive marker in Brazilian patients with sickle cell disease.

Authors:  M S Gonçalves; I L Queiroz; S A Cardoso; A Zanetti; A C Strapazoni; E Adorno; A Albuquerque; A Sant'Ana; M G dos Reis; A Barral; M Barral Netto
Journal:  Braz J Med Biol Res       Date:  2001-10       Impact factor: 2.590

Review 6.  Transfusion management of sickle cell disease.

Authors:  A S Wayne; S V Kevy; D G Nathan
Journal:  Blood       Date:  1993-03-01       Impact factor: 22.113

7.  Microvascular blood flow and stasis in transgenic sickle mice: utility of a dorsal skin fold chamber for intravital microscopy.

Authors:  Venkatasubramaniam S Kalambur; Hemchandra Mahaseth; John C Bischof; Miroslaw C Kielbik; Thomas E Welch; Asa Vilbäck; David J Swanlund; Robert P Hebbel; John D Belcher; Gregory M Vercellotti
Journal:  Am J Hematol       Date:  2004-10       Impact factor: 10.047

8.  Delayed hemolytic transfusion reaction presenting as sickle-cell crisis.

Authors:  W J Diamond; F L Brown; P Bitterman; H G Klein; R J Davey; R M Winslow
Journal:  Ann Intern Med       Date:  1980-08       Impact factor: 25.391

9.  Chemokine CXCL1/KC and its receptor CXCR2 are responsible for neutrophil chemotaxis in adenoviral keratitis.

Authors:  Ashish V Chintakuntlawar; James Chodosh
Journal:  J Interferon Cytokine Res       Date:  2009-10       Impact factor: 2.607

10.  Cytokine production in IgG-mediated red cell incompatibility.

Authors:  R D Davenport; M Burdick; S A Moore; S L Kunkel
Journal:  Transfusion       Date:  1993-01       Impact factor: 3.157

View more
  20 in total

Review 1.  Neutrophils, platelets, and inflammatory pathways at the nexus of sickle cell disease pathophysiology.

Authors:  Dachuan Zhang; Chunliang Xu; Deepa Manwani; Paul S Frenette
Journal:  Blood       Date:  2016-01-12       Impact factor: 22.113

2.  Vaso-occlusion in sickle cell disease: pathophysiology and novel targeted therapies.

Authors:  Deepa Manwani; Paul S Frenette
Journal:  Blood       Date:  2013-09-19       Impact factor: 22.113

Review 3.  Pathophysiology of Sickle Cell Disease.

Authors:  Prithu Sundd; Mark T Gladwin; Enrico M Novelli
Journal:  Annu Rev Pathol       Date:  2018-10-17       Impact factor: 23.472

4.  Single-dose MGTA-145/plerixafor leads to efficient mobilization and in vivo transduction of HSCs with thalassemia correction in mice.

Authors:  Chang Li; Kevin A Goncalves; Tamás Raskó; Amit Pande; Sucheol Gil; Zhinan Liu; Zsuzsanna Izsvák; Thalia Papayannopoulou; John C Davis; Hans-Peter Kiem; André Lieber
Journal:  Blood Adv       Date:  2021-03-09

Review 5.  Anemia: progress in molecular mechanisms and therapies.

Authors:  Vijay G Sankaran; Mitchell J Weiss
Journal:  Nat Med       Date:  2015-03       Impact factor: 53.440

6.  Cytokine and chemokine patterns across 100 days after hematopoietic stem cell transplantation in children.

Authors:  Joseph DiCarlo; Rajni Agarwal-Hashmi; Ami Shah; Paul Kim; Laila Craveiro; Renna Killen; Yael Rosenberg-Hasson; Holden Maecker
Journal:  Biol Blood Marrow Transplant       Date:  2013-12-04       Impact factor: 5.742

7.  Intravenous immunoglobulins modulate neutrophil activation and vascular injury through FcγRIII and SHP-1.

Authors:  Jung-Eun Jang; Andrés Hidalgo; Paul S Frenette
Journal:  Circ Res       Date:  2012-03-13       Impact factor: 17.367

8.  Increase of serum fractalkine and fractalkine gene expression levels in sickle cell disease patients.

Authors:  Selma Unal; Ozlem Ozdemir; Ahmet Ata Ozcimen; Yesim Oztas
Journal:  Int J Hematol       Date:  2014-12-06       Impact factor: 2.490

9.  Molecular basis of glycosaminoglycan heparin binding to the chemokine CXCL1 dimer.

Authors:  Krishna Mohan Poluri; Prem Raj B Joseph; Kirti V Sawant; Krishna Rajarathnam
Journal:  J Biol Chem       Date:  2013-07-17       Impact factor: 5.157

10.  Hydroxyurea and a cGMP-amplifying agent have immediate benefits on acute vaso-occlusive events in sickle cell disease mice.

Authors:  Camila Bononi Almeida; Christoph Scheiermann; Jung-Eun Jang; Colette Prophete; Fernando Ferreira Costa; Nicola Conran; Paul S Frenette
Journal:  Blood       Date:  2012-07-25       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.